Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis

We have recently shown that non-viral gene therapy can stabilise the decline of lung function in patients with cystic fibrosis (CF). However, the effect was modest, and more potent gene transfer agents are still required. Fuson protein (F)/Hemagglutinin/Neuraminidase protein (HN)-pseudotyped lentivi...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Thorax
Auteurs principaux: Alton, Eric W F W, Beekman, Jeffery M, Boyd, A Christopher, Brand, June, Carlon, Marianne S, Connolly, Mary M, Chan, Mario, Conlon, Sinead, Davidson, Heather E, Davies, Jane C, Davies, Lee A, Dekkers, Johanna F, Doherty, Ann, Gea-Sorli, Sabrina, Gill, Deborah R, Griesenbach, Uta, Hasegawa, Mamoru, Higgins, Tracy E, Hironaka, Takashi, Hyndman, Laura, McLachlan, Gerry, Inoue, Makoto, Hyde, Stephen C, Innes, J Alastair, Maher, Toby M, Moran, Caroline, Meng, Cuixiang, Paul-Smith, Michael C, Pringle, Ian A, Pytel, Kamila M, Rodriguez-Martinez, Andrea, Schmidt, Alexander C, Stevenson, Barbara J, Sumner-Jones, Stephanie G, Toshner, Richard, Tsugumine, Shu, Wasowicz, Marguerite W, Zhu, Jie
Format: Artigo
Langue:Inglês
Publié: BMJ Publishing Group 2017
Sujets:
Cystic Fibrosis
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5284333/
https://ncbi.nlm.nih.gov/pubmed/27852956
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/thoraxjnl-2016-208406
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires